-
Product Insights
NewEpilepsy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Epilepsy Clinical Trial Report Overview A total of 3474 epilepsy clinical trials were conducted as of April 2024. The epilepsy clinical trial report provides a comprehensive understanding of the epilepsy clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      North America ·      Europe ·      Asia-Pacific ·      ...
-
Product Insights
Clinical Trials Scorecard for Investigations in 2023
Clinical Trials Scorecard Overview The greatest number of clinical trials planned for 2023 were in Phase II. Q2 had the highest number of trials for 2023, with non-industry sponsors making up the largest share of trials. Furthermore, Oncology was the top therapy area for trials in 2023. The top indication for trials was pain, followed by solid tumor. Buy the Full Report to Know More about the Clinical Trials Scorecard Download a Free Sample Report The clinical trials scorecard report...
-
Sector Analysis
NewBronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
Bronchiectasis Market Report Overview The Bronchiectasis market across the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China) was valued at $1.4 billion in 2023 and the market will grow at a CAGR of more than 3% from 2023 to 2033. The 7MM (China, Japan, the United Kingdom, Spain, Italy, Germany, France, and the US). The market growth is attributed to the launch of brensocatib and an increase in the number of diagnosed prevalent cases of bronchiectasis. Bronchiectasis Market...
-
Product Insights
NewDecompensated Cirrhosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Decompensated Cirrhosis Clinical Trial Report Overview A total of 227 Decompensated Cirrhosis clinical trials were conducted as of April 2024. The Decompensated Cirrhosis Clinical Trial report provides an overview of the Decompensated Cirrhosis Clinical Trial scenario. This report provides top-line data relating to the clinical trials on Decompensated Cirrhosis. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Product Insights
NewMycosis Fungoides Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Mycosis Fungoides Clinical Trial Report Overview A total of 328 mycosis fungoides clinical trials were conducted as of April 2024. The mycosis fungoides clinical trial report provides a comprehensive understanding of the mycosis fungoides clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       North America ·       ...
-
Product Insights
NewPulmonary Tuberculosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Pulmonary Tuberculosis Clinical Trial Report Overview A total of 504 pulmonary tuberculosis clinical trials were conducted as of April 2024. The pulmonary tuberculosis clinical trial report provides a comprehensive understanding of the pulmonary tuberculosis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·      North America ·      ...
-
Sector Analysis
NewAmyotrophic Lateral Sclerosis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2029
Amyotrophic Lateral Sclerosis Market Report Overview Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a severely debilitating, rare, and ultimately fatal neurodegenerative condition caused by a combination of genetic and environmental factors. However, the causative pathogenic mechanisms in ALS remain unclear. The condition is characterized by progressive degeneration of both upper (UMNs) and lower motor (LMNs) neurons that leads to death, frequently from respiratory failure, within a few years. The 8MM includes the US, France, Germany,...
-
Product Insights
NewSystemic Sclerosis (Scleroderma) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Systemic Sclerosis (Scleroderma) Clinical Trial Report Overview A total of 683 systemic sclerosis clinical trials were conducted as of April 2024. The systemic sclerosis clinical trial report provides a comprehensive understanding of the systemic sclerosis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·      North America...
-
Sector Analysis
NewFriedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Report Overview Friedreich's Ataxia (FRDA) is a rare, genetic disorder. It is progressive and typically manifests between the ages of 10 and 15. The disorder is characterized by a gradual decline in coordination, muscle strength, and endurance. Individuals with FRDA often become reliant on wheelchairs as the condition advances. The Friedreich Ataxia (FRDA) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast,...